PULMONARY EMPHYSEMA IN ALPHA-1 ANTITRYPSIN DEFICIENCY

Clinical trials for PULMONARY EMPHYSEMA IN ALPHA-1 ANTITRYPSIN DEFICIENCY explained in plain language.

Never miss a new study

Get alerted when new PULMONARY EMPHYSEMA IN ALPHA-1 ANTITRYPSIN DEFICIENCY trials appear

Sign up with your email to follow new studies for PULMONARY EMPHYSEMA IN ALPHA-1 ANTITRYPSIN DEFICIENCY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Two-Year safety check for promising Alpha-1 lung therapy

Disease control ENROLLING_BY_INVITATION

This study aims to gather two more years of safety data for a weekly intravenous treatment in people with lung damage caused by Alpha-1 Antitrypsin Deficiency. It is an extension of a previous trial, enrolling about 290 participants who will receive the treatment for 104 weeks. T…

Matched conditions: PULMONARY EMPHYSEMA IN ALPHA-1 ANTITRYPSIN DEFICIENCY

Phase: PHASE3 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control

Last updated Mar 20, 2026 14:48 UTC

PULMONARY EMPHYSEMA IN ALPHA-1 ANTITRYPSIN DEFICIENCY

Get alerted when new PULMONARY EMPHYSEMA IN ALPHA-1 ANTITRYPSIN DEFICIENCY trials appear

Two-Year safety check for promising Alpha-1 lung therapy